EE300 Cost Effectiveness of Momelotinib Vs Other Treatments for Myelofibrosis from a US Payer Perspective.
Saved in:
| Title: | EE300 Cost Effectiveness of Momelotinib Vs Other Treatments for Myelofibrosis from a US Payer Perspective. |
|---|---|
| Authors: | Liu, T1 (AUTHOR), Purser, M1 (AUTHOR), Gong, C2 (AUTHOR), Elsea, D2 (AUTHOR), Niehoff, N1 (AUTHOR), Dlotko, E3 (AUTHOR), Migliaccio-Walle, K.2 (AUTHOR), Samyshkin, Y4 (AUTHOR) |
| Source: | Value in Health. 2024 Supplement, Vol. 27 Issue 6, pS112-S112. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 10983015 |
|---|---|
| DOI: | 10.1016/j.jval.2024.03.599 |
